Biotech Values

[iwfal]

Conatus - HCV

No patients in the trial receive interferon, and the variable between the two trial arms is not the experimental drug, CTS-1027, as one might, but rather is ribavirin. I.e. one of the two trial arms is CTS-1027 monotherapy for 24 weeks!

Odder is that the trial to which you are referring is 1027 vs 1027 plus rib despite the fact that in a different trial for the same drug they note:

a) 1027 is not an antiviral and has minimal efficacy by itself

b) 1027 is hypothesized to be a potentiator of IFN

Just kinda odd what combo's they are trying.